$108.52
Value $189B
ABT and TRUP stock compared: price, dividend, valuation and results, from SEC filings.
$108.52
Value $189B
$36.16
Value $1.6B
Abbott Laboratories (ABT) has a market value of $189B and Trupanion (TRUP) $1.6B. Over the last year, with dividends, ABT moved -15.7% and TRUP -4.2%. The P/E is 40.1 for ABT and 59.0 for TRUP. Dividend yield: ABT 2.32%, TRUP none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$189B
TRUP$1.6B
ABT is 120 times TRUP
Revenue, 12 months
ABT$48.2B
TRUP$1.6B
ABT is 31 times TRUP
Net income, 12 months
ABT$4.7B
TRUP$27M
ABT is 177 times TRUP
Operating margin
ABT13.8%
TRUP1.8%
12.0 points apart
ROIC
ABT6.3%
TRUP5.0%
1.3 points apart
P/E
ABT40.1
TRUP59.0
TRUP is 1.5 times ABT
Dividend yield
ABT2.3%
TRUP0.0%
2.3 points apart
5-year return
ABT-8.3%
TRUP-72.2%
63.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-8.3%
TRUP-72.2%
| Period | ABTWith dividends | TRUPWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -15.7%Price -17.7% | -4.2%Price -4.2% |
| 3 years since November 16, 2023 | +14.2%+4.5% a yearPrice +7.2% | +39.5%+11.7% a yearPrice +39.5% |
| 5 years since November 15, 2021 | -8.3%-1.7% a yearPrice -17.0% | -72.2%-22.6% a yearPrice -72.2% |
| 10 years since November 16, 2016 | +224.5%+12.5% a yearPrice +169.0% | +119.2%+8.2% a yearPrice +119.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesTRUPTrupanion
| Price | $108.52 | $36.16 |
|---|---|---|
| Market value | $189B | $1.6B |
| Enterprise value (EV) | $215B | $1.3B |
| P/E | 40.1 | 59.0 |
| P/E, 5-year median | 33.7 | – |
| P/B | 3.7 | 3.9 |
| EV/EBIT | 32.4 | 45.9 |
| Free cash flow yield | 3.6% | 5.5% |
| Revenue, 12 months | $48.2B | $1.6B |
|---|---|---|
| Net income, 12 months | $4.7B | $27M |
| Free cash flow, 12 months | $6.8B | $87M |
| Earnings per share, 12 months | $2.69 | $0.61 |
| Revenue growth, year on year | 5.7% | 12.0% |
| Revenue growth a year, past | +5.1%over 5 years | +23.5%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | 16.8% |
|---|---|---|
| Operating margin | 13.8% | 1.8% |
| Net margin | 9.8% | 1.7% |
| ROIC | 6.3% | 5.0% |
| ROE | 9.1% | 6.8% |
| Cash | $4.3B | $397M |
|---|---|---|
| Total debt | $31.2B | $104M |
| Net debt / EBITDA | 3.3 | -6.7 |
| Interest cover | 6.7× | 2.9× |
| Dividend yield | 2.3% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | – |
| Shareholder yield | 2.8% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($189B) is about 120.1 times Trupanion ($1.6B), at today's prices.
Since November 16, 2016, ABT's price moved +169.0% and TRUP's +119.2%. With dividends: ABT +224.5% (+12.5% a year), TRUP +119.2% (+8.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.32% for Abbott Laboratories and none for Trupanion. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 40.1 for ABT and 59.0 for TRUP. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 1.7% for Trupanion, and the operating margin 13.8% and 1.8%. Revenue was $48.2B and $1.6B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.